Screening for asymptomatic diabetes and metabolic comorbidities in pediatric patients during therapy for acute lymphoblastic leukemia.
Larouche ValérieCaroline BellavancePauline TiboutSebastien BergeronDavid SimonyanJulie GagnéPublished in: Journal of pediatric endocrinology & metabolism : JPEM (2021)
Increase of body mass index in our ALL pediatric patients occurred during the first months of therapy and plateaued after a year of treatment. We should target this population for early obesity prevention. HbA1c levels measured during therapy did not reveal diabetes criteria. Hence, fasting blood glucose levels are sufficient to monitor ALL pediatric patients' glycemia.
Keyphrases
- blood glucose
- glycemic control
- type diabetes
- acute lymphoblastic leukemia
- body mass index
- insulin resistance
- cardiovascular disease
- weight loss
- weight gain
- metabolic syndrome
- blood pressure
- physical activity
- stem cells
- genome wide
- gene expression
- allogeneic hematopoietic stem cell transplantation
- skeletal muscle
- acute myeloid leukemia
- dna methylation
- replacement therapy
- smoking cessation
- high fat diet induced